Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole (2010)

Peer-Reviewed Study · Brits M; Liebenberg W; de Villiers MM · March 2010

Brits M et al., 2010-03: A stability study showing that the preferred polymorph C degrades into the poorly absorbed form A under heat and humidity, that trace form A accelerates the change, and that four of seven products tested already contained traces. In some tablets the conversion cut shelf life to under a month and pushed dissolution below USP and FDA limits.

Results showed that form C was converted to the thermodynamic stable, least soluble form A with increased temperatures and moisture, and at constant temperature and relative humidity this transformation was significantly increased when trace amounts of form A was present in the tablets. Four out of the seven products tested contained trace amounts of form A.

abstract

Brits M et al., 2010-03: A stability study showing that the preferred polymorph C degrades into the poorly absorbed form A under heat and humidity, that trace form A accelerates the change, and that four of seven products tested already contained traces. In some tablets the conversion cut shelf life to under a month and pushed dissolution below USP and FDA limits. Study type: pharmaceutical stability/analytical study (accelerated stability, JMAEK kinetics, ICH conditions 30 C/65% RH and 40 C/75% RH). N: seven tablet products. Country: South Africa (North-West University). No patients. Funder/conflicts: not stated in the abstract. Manufacturer names not given in the abstract. Comparator: reference polymorphs. This is the paper behind the practical advice in MBA-35 that polymorph-C tablets should be stored cool. Also filed as MBD-28 (claims C5, C8).